Giuliani Mario Germano's Form 4 filing

Royalty Pharma plc (RPRX) · filed Dec 5, 2022

Accession no.: 0001140361-22-044471
Filed: Dec 5, 2022, 4:44 PM ET
Trade date: Dec 1-2, 2022
Filing delay: 4 days
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $16.0M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Giuliani Mario GermanoCIK 0001814882	Director, 10% Owner
Skyeline Management LtdCIK 0001814877	10% Owner
MGG Strategic SICAF SIF S.A. - MGG StrategicCIK 0001814889	10% Owner
Avara Management LtdCIK 0001814934	10% Owner
MGG Strategic SICAF SIF S.A.CIK 0001922189	10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Dec 1, 2022	Class A Ordinary Shares	SSaleDisposed	−165,000	$44.11^F6	−$7,277,325	22,225,000	Indirect
Dec 2, 2022	Class A Ordinary Shares	SSaleDisposed	−197,766	$43.98^F7	−$8,697,412.48	7,879,374	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.005 to $44.19 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.80 to $44.20 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit List: Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)